Debt rising as profit falls
Total debt rose 50.4% while net profit fell 27.4% — worth checking how the balance sheet is being funded.
Importance 76 / 95 · financial health
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Total debt rose 50.4% while net profit fell 27.4% — worth checking how the balance sheet is being funded.
Importance 76 / 95 · financial health
Revenue grew 3.2% but profit declined 27.4%, so the company kept less of each rupee of revenue as profit.
Importance 74 / 95 · growth
EBITDA margin dropped 6.4 percentage points in a single year, from 29.5% to 23.2% — worth investigating.
Importance 70 / 95 · anomaly
Net worth compounded at 18.8% a year over 4 years (₹19,212 → ₹38,231).
Importance 57 / 95 · financial health
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 9.3% a year over 4 years, from ₹14,405 cr in FY2022 to ₹20,533 cr in FY2026. Net profit grew 18.7% a year over the same period.
Revenue grew 3.2% but profit declined 27.4%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Over 4 years profit compounded at 17.5% a year while revenue compounded at 11.8% a year — though FY2023 saw a one-off step-change of 107% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit fell 27.4% year on year (FY2025 → FY2026).
Revenue has compounded at 11.8% a year over 4 years (₹21,545 → ₹33,700) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹8,698 cr (down 1.5% on the same quarter last year) and net profit ₹913 cr (down 31.7%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹913 cr, down 31.7% from ₹1,337 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 EBITDA margin was 21.7%, down 4.74 percentage points from 26.4% a year earlier.
Rule QTR_MARGIN_CHANGED_YOY
Q2 FY27 net profit declined 31.7% while revenue declined 1.5% vs the same quarter last year — a gap of 30.2 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 8,381 | +15.8% | 1,404 | +1.7% | 16.8% |
| Q4 FY25 | 8,528 | +19.9% | 1,587 | +21.1% | 18.6% |
| Q1 FY26 | 8,572 | +11.4% | 1,410 | +1.3% | 16.4% |
| Q2 FY26 | 8,828 | +9.8% | 1,337 | −0.4% | 15.1% |
| Q3 FY26 | 8,753 | +4.4% | 1,190 | −15.3% | 13.6% |
| Q4 FY26 | 7,546 | −11.5% | 221 | −86.1% | 2.9% |
| Q1 FY27 | 8,100 | −5.5% | 436 | −69.1% | 5.4% |
| Q2 FY27 | 8,698 | −1.5% | 913 | −31.7% | 10.5% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 27.3% in FY2026, against 21.4% in FY2022. ROE was 10.7% and ROCE 12.7% in FY2026.
ROE declined from 18.4% to 11.5% year on year.
Rule ROE_DETERIORATED_YOY
EBITDA margin has ranged from 19.7% to 31.5% over 4 years and sits at 23.2% now.
Debt-to-equity was 0.17x in FY2026, against 0.12x in FY2022; interest coverage 29.67x. Operating cash flow was 1.45x net profit.
Total debt rose 50.4% while net profit fell 27.4% — worth checking how the balance sheet is being funded.
Rule DEBT_UP_EARNINGS_DOWN
Net worth compounded at 18.8% a year over 4 years (₹19,212 → ₹38,231).
Free cash flow has been positive in 5 of the last 5 years.
Within its 12-company Pharmaceuticals peer group, it ranks 10 of 12 on return on equity and 10 of 12 on EBITDA margin. Its P/E of 42.1 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
DRREDDY · 11th of 12 · set median 14.8%
DRREDDY · 10th of 12 · set median 28.7%
DRREDDY · 10th of 12 · set median 14.4%
DRREDDY · 6th of 12 · set median 45.3×
Trades at 3.04× book — 36% below the pharmaceuticals median of 4.74×.
Rule PB_BELOW_PEERS
On the trailing twelve months. Last full year: P/E 27.9× · P/S 3.3× · ROE 11.5%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 11.4% over 1 year, up 23.1% over 3 years (7.2% a year) and up 48.8% over 5 years (8.3% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 0.5% below its 52-week high.
Over 4 years profit compounded at 17.5% a year while the stock returned 7.2% a year — but FY2022 profit (₹2,183) was well below the through-cycle level (~₹4,507), so this rate is inflated by the recovery from a low base.
Rule STOCK_LAGGED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 14,405 | 16,963 | 19,484 | 23,115 | 20,533 |
| Total income | 14,887 | 17,554 | 20,346 | 24,119 | 22,222 |
| EBITDA | 3,076 | 4,806 | 6,789 | 8,385 | 5,607 |
| Profit before tax | 2,224 | 3,866 | 5,791 | 7,236 | 4,251 |
| Net profit | 1,623 | 2,613 | 4,342 | 5,349 | 3,220 |
| EPS (₹) | 97.8 | 157.4 | 260.9 | 64.2 | 38.7 |
| Net worth | 18,336 | 20,474 | 24,241 | 28,857 | 31,366 |
| Total debt | 2,191 | 51 | 710 | 3,386 | 5,419 |
| Operating cash flow | 1,339 | 5,053 | 3,450 | 4,225 | 4,661 |
| Free cash flow | 37 | 4,077 | 2,089 | 1,918 | 2,637 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 17.8 | 14.9 | 18.6 | -11.2 |
| Profit growth YoY | — | 61.0 | 66.2 | 23.2 | -39.8 |
| Profitability | |||||
| EBITDA margin % | 21.4 | 28.3 | 34.8 | 36.3 | 27.3 |
| Net margin % | 10.9 | 14.9 | 21.3 | 22.2 | 14.5 |
| Return on equity % | 8.9 | 13.5 | 19.4 | 20.1 | 10.7 |
| Return on capital % | 11.0 | 18.9 | 25.6 | 25.7 | 12.7 |
| Leverage & cash | |||||
| Debt to equity | 0.12 | 0.00 | 0.03 | 0.12 | 0.17 |
| Cash flow ÷ profit | 0.82 | 1.93 | 0.79 | 0.79 | 1.45 |
| Current ratio | 2.28 | 3.16 | 3.22 | 1.91 | 1.66 |